A Case Report of Renal Sympathetic Denervation for the Treatment of Polymorphic Ventricular Premature Complexes

Expanding Horizons

Marcio Galindo Kiuchi, MD, MSc, PhD, Frederico Puppim Vitorio, MD, Gustavo Ramalho da Silva, MD, Luís Marcelo Rodrigues Paz, MD, and Gladyston Luiz Lima Souto, MD, PhD

Abstract: Premature ventricular complexes are very common, appearing most frequently in patients with hypertension, obesity, sleep apnea, and structural heart disease. Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of ventricular arrhythmias. Recently, Armaganian et al reported the relevance of sympathetic activation in patients with ventricular arrhythmias and suggested a potential role for catheter-based renal sympathetic denervation in reducing the arrhythmic burden.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic premature ventricular complexes on a 24-hour Holter monitor. Beginning 1 year prior, the patient experienced episodes of presyncope, syncope, and tachycardia palpitations. The patient was taking losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used previously but was not successful for controlling the episodes. The 24 hour Holter performed after the onset of sotalol 160 mg twice daily showed a heart rate ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic premature ventricular complexes; 3 episodes of nonsustained ventricular tachycardia, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. Cardiac magnetic resonance imaging with gadolinium perfusion performed at rest and under pharmacological stress with dipyridamole showed increased left atrial internal volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic premature ventricular complexes on a 24-hour Holter monitor. Beginning 1 year prior, the patient experienced episodes of presyncope, syncope, and tachycardia palpitations. The patient was taking losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used previously but was not successful for controlling the episodes. The 24 hour Holter performed after the onset of sotalol 160 mg twice daily showed a heart rate ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic premature ventricular complexes; 3 episodes of nonsustained ventricular tachycardia, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. Cardiac magnetic resonance imaging with gadolinium perfusion performed at rest and under pharmacological stress with dipyridamole showed increased left atrial internal volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic premature ventricular complexes on a 24-hour Holter monitor. Beginning 1 year prior, the patient experienced episodes of presyncope, syncope, and tachycardia palpitations. The patient was taking losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used previously but was not successful for controlling the episodes. The 24 hour Holter performed after the onset of sotalol 160 mg twice daily showed a heart rate ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic premature ventricular complexes; 3 episodes of nonsustained ventricular tachycardia, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. Cardiac magnetic resonance imaging with gadolinium perfusion performed at rest and under pharmacological stress with dipyridamole showed increased left atrial internal volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic premature ventricular complexes on a 24-hour Holter monitor. Beginning 1 year prior, the patient experienced episodes of presyncope, syncope, and tachycardia palpitations. The patient was taking losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used previously but was not successful for controlling the episodes. The 24 hour Holter performed after the onset of sotalol 160 mg twice daily showed a heart rate ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic premature ventricular complexes; 3 episodes of nonsustained ventricular tachycardia, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. Cardiac magnetic resonance imaging with gadolinium perfusion performed at rest and under pharmacological stress with dipyridamole showed increased left atrial internal volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic premature ventricular complexes on a 24-hour Holter monitor. Beginning 1 year prior, the patient experienced episodes of presyncope, syncope, and tachycardia palpitations. The patient was taking losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used previously but was not successful for controlling the episodes. The 24 hour Holter performed after the onset of sotalol 160 mg twice daily showed a heart rate ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic premature ventricular complexes; 3 episodes of nonsustained ventricular tachycardia, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. Cardiac magnetic resonance imaging with gadolinium perfusion performed at rest and under pharmacological stress with dipyridamole showed increased left atrial internal volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.

The only drug used postprocedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value dropped to 132/86 mmHg, the mean systolic/diastolic volume, preserved systolic global biventricular function, and an absence of infarcted or ischemic areas. The patient underwent bilateral renal sympathetic denervation.
pursue for PVCs that are polymorphic and refractory to medical treatment is not clear. Potential treatment options include mapping and ablating them one by one or attempting a new, alternative therapy.

Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of ventricular arrhythmias. Recently, Armaganijan et al reported the relevance of sympathetic activation in patients with ventricular arrhythmias and suggested a potential role for catheter-based renal sympathetic denervation in reducing the arrhythmic burden.

In this report, we describe a 32-year-old hypertensive male patient presenting with a high incidence of polymorphic PVCs on a 24 hour Holter monitor. One year prior, the patient began experiencing episodes of presyncope, syncope, and tachycardia palpitations. The ethics committee, comprising Paola Baars Gomes Moises, Luis Marcelo Rodrigues Paz, Humberto Cesar Tinoco, and Jonny Shogo Takahashi, approved this case study. Written informed consent was provided by the patient. The patient was taking Losartan 100 mg/day, which kept his blood pressure (BP) under control, and sotalol 160 mg twice daily. Bisoprolol 10 mg/day was used in the past but was not successful in controlling the episodes. The physical examination of the patient was normal, with the exception of high BP (mean of 4 measures taken during 2 different office visits, BP = 162/100 mmHg) and PVCs. The electrocardiogram and treadmill stress test showed a sinus rhythm and no abnormalities aside from PVCs. Furthermore, on the treadmill test the patient did not present ischemia and his metabolic equivalents of task (METs) reached 8.23. The mean systolic/diastolic 24 hour ambulatory BP measurement was 144/95 mmHg. The first 24 hour Holter monitor, performed before the use of bisoprolol or sotalol, showed an HR ranging between 64 (minimum)–85 (average)–136 (maximum) bpm; 28,983 polymorphic PVCs; 8 episodes of NSVT, the largest composed of 11 beats at a rate of 201 bpm; and 100 isolated atrial ectopic beats. The second 24 hour Holter monitor, performed after the onset of sotalol 160 mg twice daily, showed an HR ranging between 48 (minimum)–78 (average)–119 (maximum) bpm; 14,286 polymorphic PVCs; 3 episodes of NSVT, the largest composed of 4 beats at a rate of 197 bpm; and 14 isolated atrial ectopic beats. The echocardiogram and tilt table test were normal. We further investigated this patient’s symptoms using cardiac magnetic resonance imaging with gadolinium perfusion at rest and under pharmacological stress with dipyridamole. This assessment showed an increased left atrial internal volume (101 mL), preserved systolic global biventricular function (with a left ventricular ejection fraction measured by Simpson method of 58.2%), and the absence of infarcted or ischemic areas. Arrhythmogenic right ventricular cardiomyopathy was not observed (Figure 1A and B). The final step of this investigation involved an electrophysiological study, which showed normal sinus function, normal electrical conduction through the His-Purkinje system, atrial electrical stability, and ventricular electrical stability (without triggering sustained ventricular tachycardia), as shown in Figure 2.

The renal sympathetic denervation procedure was performed in the catheterization laboratory with direct visualization using fluoroscopy and a radiopaque contrast agent. We used the EnSite Velocity three-dimensional mapping system (St. Jude Medical, St. Paul, MN) to construct the anatomy of the renal arteries and aorta, as well as for radiofrequency application at the selected sites. The patient remained under unconscious sedation. The patient underwent catheterization of the right femoral artery by the standard Seldinger technique, which was performed using a 7-Fr valved short sheath after subcutaneous injection of local anesthetic. Subsequently, this was replaced with a steerable long sheath (Agilis, St. Jude Medical) using the standard ‘‘over the wire’’ technique. Unfractionated heparin was administered intravenously, targeting an activated
coagulation time between 250 and 350 seconds. This sheath was advanced to the level of the renal arteries, and the ostia was located using nonselective aortography. The introducer was then carefully deflected to anchor at the ostium of each renal artery to introduce the ablation catheter with an open irrigated tip (St. Jude Medical), as shown in Figure 3. The procedure was performed with no complications, and the patient remained clinically stable and awoke properly from sedation. Intravenous protamine was infused at the end of the procedure, manual compression of the femoral artery was performed for 15 minutes, and a compressive dressing was applied. No vascular complications resulted from the procedure. The patient was discharged after a 24 hour hospitalization period, and he was clinically stable and walking without difficulty.

We were unable to find an electrical signal in the kidney, even while creating an extensive map of the renal arteries in search of electric potential from the autonomic nervous system. However, the sympathetic nerves are largely located in the adventitia layer, 1.5 to 2 mm from the lumen of the renal artery,15 and the SYMPLYCITY HTN-3 trial16 found that a greater number of ablated spots was a predictor of success, as this may cause more destruction of the sympathetic arterial nerves.

The only drug used after the procedure was losartan 25 mg/day. Three months after the patient underwent renal sympathetic denervation, the mean BP value taken in our office dropped to 132/86 mmHg, the mean systolic/diastolic 24 hour ambulatory BP measurement was reduced to 128/83 mmHg, and the

---

**FIGURE 2.** Electrophysiological study showing ventricular electrical stability.

**FIGURE 3.** Using the EnSite Velocity three-dimensional mapping system for constructing the anatomy of the renal arteries and for radiofrequency application in the selected sites.
24-hour Holter monitor showed an HR ranging between 51 (minimum)–67 (average)–108 (maximum) bpm, 854 polymorphic PVCs, and no episodes of NSVT.

Even though the technique used herein is not the standard technique, we opted to perform renal sympathetic denervation because we believe that sympathetic hyperactivity is closely related to the appearance of PVCs. Other treatment options for ventricular arrhythmias, such as endocardial and epicardial ablation, which is considered the gold standard, could be utilized and should be considered for future cases.17,18

ACKNOWLEDGEMENTS

The authors thank Mr. Sérgio Oliveira and Pacemed for their technical support.

REFERENCES

1. Noheria A, Deshmukh A, Asirvatham SJ. Ablating premature ventricular complexes: justification, techniques, and outcomes. Methodist Debakey Cardiovasc J. 2015;11:109–120.

2. Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 1985;312:193–197.

3. Agarwal SK, Heiss G, Rautaharju PM, et al. Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 2010;41:588–593.

4. Ataklte F, Erqou S, Laukkanen J, et al. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. Am J Cardiol. 2013;112:1263–1270.

5. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624–650.

6. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000;36:811–823.

7. Scheinman MM. Role of the His-Purkinje system in the genesis of cardiac arrhythmia. Heart Rhythm. 2009;6:1050–1058.

8. Adams JC, Srivathan K, Shen WK. Advances in management of premature ventricular contractions. J Interv Card Electrophysiol. 2012;35:137–149.

9. Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contraction-induced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol. 2012;5:229–236.

10. Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol. 2007;49:2035–2043.

11. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005;46:1288–1294.

12. Santoro F, Biase LD, Hranitzky P, et al. Ventricular fibrillation triggered by PVCs from papillary muscles: clinical features and ablation. J Cardiovasc Electrophysiol. 2014;25:1158–1164.

13. Leenen FH. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol. 1999;15(Suppl A):2A–7A.

14. Armaganjan LV, Staico R, Moreira DA, et al. 6-month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc Interv. 2015;8:984–990.

15. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25:628–633.

16. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–227.

17. Akou T, Guler TE, Yalin K. Successful ablation of an epicardial ventricular tachycardia by video-assisted thoracoscopic. Europace. 2015;17:1116.

18. Akou T, Guler TE, Golcuk E, et al. Successful focal ablation in a patient with electrical storm in the early postinfarction period: case report. Int Med Case Rep J. 2015;8:59–63.